Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ContextVision ABOSL:CONTX 82 Debt-to-EBITDA is 0.95 as of Mar. 2026, which is 494% above its 10-year median of 0.16. GuruFocus rates OSL:CONTX with a GF Score™ of 82/100 and a GF Value™ of kr5.11 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 477 Healthcare Providers & Services companies, ContextVision AB ranks better than 71.91% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for ContextVision AB's Debt-to-EBITDA or its related term are showing as below:
OSL:CONTX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.09 Med: 0.16 Max: 1.72
Current: 0.89
During the past 13 years, the highest Debt-to-EBITDA Ratio of ContextVision AB was 1.72. The lowest was 0.09. And the median was 0.16.
OSL:CONTX's Debt-to-EBITDA is ranked better than 71.91% of 477
companies
in the Healthcare Providers & Services industry
Industry Median: 2.22
vs OSL:CONTX: 0.89
ContextVision AB (OSL:CONTX) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
ContextVision AB Debt-to-EBITDA Related Terms
ContextVision AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for ContextVision AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:CONTX vs VEEV, BTSG, TEM: Debt-to-EBITDA Comparison
For the Health Information Services subindustry, ContextVision AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ContextVision AB Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ContextVision AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ContextVision AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
ContextVision AB (OSL:CONTX) has a Debt-to-EBITDA of 0.95 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on ContextVision AB. This is 494% above median its historical median of 0.16. Over the past decade, ContextVision AB's Debt-to-EBITDA has ranged from 0.09 to 1.72. According to the industry distribution chart, ContextVision AB ranks #134 out of 477 companies in the Healthcare Providers & Services industry, placing it in the top 28.1%.
Is ContextVision AB's Debt-to-EBITDA too high?
ContextVision AB's current Debt-to-EBITDA of 0.95 is 494% above median its 10-year median of 0.16. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 1.72. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.22. ContextVision AB's value of 0.95 is 57.2% below this industry median. Based on the distribution chart, ContextVision AB ranks #134 out of 477 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, ContextVision AB has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ContextVision AB's Debt-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ContextVision AB ranks #134 out of 477 companies for Debt-to-EBITDA. This puts ContextVision AB in the upper half of its industry. The industry median Debt-to-EBITDA is 2.22. ContextVision AB's value of 0.95 is 57.2% below this benchmark. Historically, ContextVision AB's own Debt-to-EBITDA has ranged from 0.09 to 1.72 over the past decade. While the company's 10-year median is 0.16 vs. the industry median of 2.22, ContextVision AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.22, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ContextVision AB's current Debt-to-EBITDA of 0.95 is 57.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on ContextVision AB. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ContextVision AB's current Debt-to-EBITDA is 0.95, which is 494% above median its own 10-year median of 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ContextVision AB stock overvalued right now?
Based on GuruFocus' analysis, ContextVision AB (OSL:CONTX) is currently considered Significantly Undervalued. The stock's GF Value™ is kr5.11, compared to a current price of kr3.40 — trading 33.5% below its estimated fair value. The current Debt-to-EBITDA is 0.95, which is 494% above median its 10-year median of 0.16 and 57.2% below the Healthcare Providers & Services industry median of 2.22. ContextVision AB's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For ContextVision AB (OSL:CONTX), the current Debt-to-EBITDA is 0.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ContextVision AB (OSL:CONTX) Overvalued in 2026?
Based on GuruFocus' analysis, ContextVision AB stock appears to be undervalued.
The current stock price of kr3.40 is trading 33.5% below its estimated GF Value™ of kr5.11.
GuruFocus considers ContextVision AB to be Significantly Undervalued.
Key valuation signals for OSL:CONTX:
Debt-to-EBITDA: 0.95 (494% above median its 10-year median of 0.16)
GF Value™: kr5.11 vs. price of kr3.40 (33.5% below fair value)
Industry Position: 57.2% below the Healthcare Providers & Services median (#134 of 477)
No single metric tells the full story. See the OSL:CONTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ContextVision AB is a medical technology company. It develops and sells image enhancement software for medical diagnosis and artificial intelligence. Its product portfolio includes image enhancement software for 2D/3D/4D (dimensional) ultrasound, magnetic resonance imaging (MRI), X-Ray, radiography, and mammography. Its geographical segments are Asia, Europe, and America.
82GF Score
Get the complete analysis for OSL:CONTX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:CONTX has been successfully added to your 
